Gefitinib

Gefitinib Reactions 1704, p172 - 2 Jun 2018 Development of resistance in lung adenocarcinoma transforming to small cell lung cancer and squamous cell carcinoma: case report A man in his early 40’s developed resistance to gefitinib with transformation of lung adenocarcinoma to small cell lung cancer and squamous cell carcinoma. The man, who had been diagnosed with EGFR-mutated lung adenocarcinoma at the age of 41 years, started receiving oral gefitinib 250 mg/day in August 2014. Initially, gefitinib treatment showed a good clinical response. However, 11 months after gefitinib treatment, he acquired drug resistance. In November 2015, a CT showed progression in right lung lesion along with the development of new lesions in the left lung. He then took self-treatment with erlotinib [Tarceva], sorafenib and various other medications. Despite treatment, his carcinoma progressed. In February 2017, he was readmitted. A positron emission tomography-CT showed a mass in the right hilus pulmonis and multiple nodules in the bilateral lungs with high glycometabolism. Thereafter, a lung puncture biopsy was performed. A histopathological examination revealed SCLC. Thereafter, the man received etoposide and cisplatin chemotherapy. Despite this, his right lung mass progressed. A histopathological examination showed SCC. He died in April 2017 [cause of death not stated]. Author comment: "Here we reported a 41-year-old man with EGFR-mutated lung adenocarcinoma and he showed histologic transformation to both small-cell lung cancer (SCLC) and squamous cell carcinoma(SCC) after treatment of gefitinib." "[T]he patient acquired drug resistance to gefitinib after 11 months of treatment. At last, the histopathologic examination showed the patient had both SCLC and SCC, while adenocarcinoma cell was not found." Yao Y, et al. Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report. Medicine 97: e0650, No. 18, 01 May 2018. Available from: URL: http:// doi.org/10.1097/MD.0000000000010650 - China 803322808 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Gefitinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/gefitinib-zSd4Q30WTj
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46815-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p172 - 2 Jun 2018 Development of resistance in lung adenocarcinoma transforming to small cell lung cancer and squamous cell carcinoma: case report A man in his early 40’s developed resistance to gefitinib with transformation of lung adenocarcinoma to small cell lung cancer and squamous cell carcinoma. The man, who had been diagnosed with EGFR-mutated lung adenocarcinoma at the age of 41 years, started receiving oral gefitinib 250 mg/day in August 2014. Initially, gefitinib treatment showed a good clinical response. However, 11 months after gefitinib treatment, he acquired drug resistance. In November 2015, a CT showed progression in right lung lesion along with the development of new lesions in the left lung. He then took self-treatment with erlotinib [Tarceva], sorafenib and various other medications. Despite treatment, his carcinoma progressed. In February 2017, he was readmitted. A positron emission tomography-CT showed a mass in the right hilus pulmonis and multiple nodules in the bilateral lungs with high glycometabolism. Thereafter, a lung puncture biopsy was performed. A histopathological examination revealed SCLC. Thereafter, the man received etoposide and cisplatin chemotherapy. Despite this, his right lung mass progressed. A histopathological examination showed SCC. He died in April 2017 [cause of death not stated]. Author comment: "Here we reported a 41-year-old man with EGFR-mutated lung adenocarcinoma and he showed histologic transformation to both small-cell lung cancer (SCLC) and squamous cell carcinoma(SCC) after treatment of gefitinib." "[T]he patient acquired drug resistance to gefitinib after 11 months of treatment. At last, the histopathologic examination showed the patient had both SCLC and SCC, while adenocarcinoma cell was not found." Yao Y, et al. Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report. Medicine 97: e0650, No. 18, 01 May 2018. Available from: URL: http:// doi.org/10.1097/MD.0000000000010650 - China 803322808 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off